Lauréats Grants scientifiques 2022

Lauréats Grants scientifiques 2022

Lauréats de l’appel à projets Grants scientifiques 2022

Grâce à la générosité de ses donateurs, la Fondation contre le Cancer finance cette année 57 projets provenant de diverses institutions de recherche en oncologie du pays, pour un montant total de 25,7 millions d’euros.  Ces projets visent à mieux comprendre la maladie, augmenter les chances de guérison et améliorer la qualité de vie des personnes atteintes d’un cancer. En finançant les recherches les plus innovantes contre le cancer nous contribuons à transformer l’espoir en victoire.

Les lauréats sélectionnés par les conseils scientifiques indépendants sont les suivants

Recherche fondamentale : 29 projets - € 14 294 198

Équipe(s) de recherche
Institution(s)
Montant
Type de cancer
Type de traitement
Titre du projet
Agostinis Patrizia
KU Leuven
350 000 €
Mélanome
Harnessing lysosomal iron homeostasis to prevent melanoma dissemination
Beck Benjamin
ULB
598 000 €
Cancer de l'oesophage
A cellular reservoir for metaplasia and cancer initiation in the oesophagus
Callewaert Nico
UGent
359 999 €
Thérapie cellulaire
Arming therapeutic CAR-T cells with glyco-engineered suppressors of tumor-infiltrating regulatory T cells
Constantinescu Stefan
Institut de Duve
600 000 €
Leucémie
Role of the Human Thrombopoietin Receptor in Myeloproliferative Neoplasms and transition to Secondary Acute Myeloid Leukemia.
Cools Jan
KU Leuven
540 000 €
Leucémie
EZH2 as a transcriptional activator in T-ALL
Corbet Cyril
UCLouvain
580 000 €
Cancer de la zone tête et cou
Towards metabolic targeting of the minimal residual disease in head and neck cancers
De Smet Frederik & Vermeirssen Vanessa & Quintens Roel
KU Leuven & UGent & Belgian Nucleair Research Centre
480 000 €
Cancer du cerveau
Radiothérapie
Targeting radiation-induced plasticity in Glioblastoma: from fundamental insights to tailored therapeutic opportunities
Dierickx Daan
KU Leuven
400 000 €
Lymphome
Molecular characterization of hyperactive T cell receptor signaling in peripheral T cell lymphoma to uncover druggable targets
Elewaut Dirk
UGent
475 000 €
Cancer du foie
Role of endogenous NKT ligands induced by Endoplasmic Reticulum stress in NASH-driven hepatocellular carcinoma
Elia Ilaria
KU Leuven
336 000 €
Cancer de la peau
Potentiating the metabolic fitness of metastasis associated CD8+ T cells through spatial metabolomics.
Fendt Sarah-Maria
KU Leuven
600 000 €
Cancer du sein
Lipid metabolism in obesity and aging-induced cancer metastasis
Gilles Christine
ULiège
360 000 €
Studying Tissue Factor-dependent membrane protein proteolysis in metastasis
Goossens Steven
UGent
480 000 €
Leucémie
Oncogenic Role of SOX11 in T-cell acute lymphoblastic leukemia
Goriely Stanislas
ULB
478 400 €
Immunothérapie
Targeting Heme Oxygenase-1 expressing tumor associated macrophages to improve cancer immunotherapy
Gurzov Esteban & Verslype Chris & Scott Charlotte
ULB & KU Leuven & UGent
480 000 €
Cancer du foie
Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPT
Marine Jean-Christophe
KU Leuven
600 000 €
Cancer de la peau
Detection and prevention of early metastatic dissemination of melanoma
Mestdagh Pieter
UGent
510 000 €
Immunothérapie
Identifying lncRNA modulators of T-cell activation to enhance immune-checkpoint inhibition therapy
Movahedi Kiavash
VUB
478 000 €
Cancer du cerveau
Immunothérapie
Macrophage-based cell therapy for brain cancer
Noel Agnès
ULiège
600 000 €
Targeting ferroptosis resistance of metastasizing cancer cells in lymph node
Pastushenko Ievgenia
ULB
600 000 €
Defining the role of the frequently mutated epigenetic regulators in cancer
Rooman Ilse & Van Laethem Jean-Luc
VUB & ULB
476 800 €
Cancer du pancréas
InterCePPT: Interfere with Cellular Positioning in the Pancreatic Tumor
Speleman Franki
UGent
600 000 €
Neuroblastome
Single-cell and spatial multi-omics exploration of tumor intrinsic and microenvironment responses to ALK-ATR-CHK1-RRM2 axis drugging in neuroblastoma
Tissir Fadel
UCLouvain
600 000 €
Cancer du cerveau
Glioblastoma prognosis and treatment: Could DIAPH3 be a game-changer?
van der Bruggen Pierre
Institut de Duve
360 000 €
Immunothérapie
Cancer-associated neutrophils and their impact on immune cells
Van Keymeulen Alexandra
ULB
369 600 €
Cancer du sein
Deciphering the cell plasticity preceding tumor appearance in the mammary gland
van Loo Geert
UGent
480 000 €
Cancer de la peau
The impact of cell death on the cancer stem cell niche in non-melanoma skin cancer
Van Vlierberghe Pieter
UGent
600 000 €
Leucémie
PU.1 as driver of leukemic stem cells in human T cell acute lymphoblastic leukemia
Vanden Berghe Tom
UAntwerpen
462 400 €
Neuroblastome
Studying the epigenetic regulation of ferroptosis in high-risk neuroblastoma
Vleminckx Kris
UGent
439 999 €
Liposarcome
Thérapie génique
CRISPR-mediated mapping of genetic dependencies in well-differentiated and dedifferentiated liposarcoma

Recherche translationnelle et clinique :
21 projets - € 9 557 935

Équipe(s) de recherche
Institution(s)
Montant
Type de cancer
Type de traitement
Titre du projet
Baron Frédéric & Humblet-Baron Stéphanie & Marchant Arnaud
ULiège & KU Leuven & ULB
600 000 €
Leucémie
Systems Vaccinology in allogeneic hematopoietic stem cell transplant recipients
Blanpain Cédric
ULB
600 000 €
Cancer du poumon
Defining and targeting tumor cell states responsible for resistance to therapy
Buisseret Laurence
ULB
300 00 €
Cancer du sein
Immunothérapie
Impact of immunotherapy on triple-negative breast cancer microenvironement
Ceelen Wim & Van Ginderachter Jo
UGent & VUB
512 500 €
Cancer colorectal
Immunothérapie
Engineering the tumor immune microenvironment in colorectal peritoneal metastases by locoregional delivery of toll like receptor agonists
De Geest Bruno & Laoui Damya
UGent & VUB
450 000 €
Immunothérapie
A translational cancer vaccination approach based on co-delivery of tumor antigen and Toll-like receptor agonists
De Moerloose Barbara
UGent
300 000 €
Leucémie
Integration of genome, epigenome, and transcriptome in juvenile myelomonocytic leukemia and functional analysis of circular RNAs as novel biomarker and/or therapeutic targets
De Preter Katleen
UGent
588 238 €
Cancer de la peau, du poumon et du rein
Immunothérapie
NIPITplus, a multi-cancer blood test to predict immune checkpoint inhibitor response and monitor toxicity
De Wever Olivier
UGent
400 000 €
Sarcome
Exploiting patient-derived models to guide therapeutic decision making in soft tissue sarcoma
Desmedt Christine
KU Leuven
598 970 €
Cancer du sein
MetLob: A post-mortem tissue donation study dedicated to Metastatic Lobular breast cancer
Flamen Patrick
Institut Jules Bordet
299 345 €
Cancer colorectal et du pancréas
Traitement ciblé
Lu-177-FAPI (fibroblast activation protein inhibitor) radioligand therapy in colorectal and pancreatic cancers: Phase 1 study based on dosimetric rationale
Jacobs Sandra & Van Damme An
BSPHO
400 000 €
Cancer du cerveau
Prospective international phase-III trials to improve treatment effectiveness and quality of survival in children with embryonal brain tumours
Lambrecht Maarten & De Saint Hubert Marijke
KU Leuven & SCK-CEN
523 047 €
Radiothérapie
ProPOSE: Proton therapy in Pregnancy for Optimal, Safe and Effective cancer treatment
Michaux Lucienne
UZ Leuven
448 284 €
Lymphome
Improved Cytogenomic Diagnosis in Lymphoma: Opportunities of Optical Genome Mapping and Long-read Sequencing
Nuyts Sandra & Nevens Daan
UZ Leuven & UZ Antwerpen
400 000
Cancer de la zone tête et cou
Radiothérapie et immunothérapie
PROLoNg-trial: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck cancer: a randomized phase III study
Peeters Marc & Verslype Chris
UZ Antwerpen & KU Leuven
549 874 €
Neoplasie neureoendocrinienne (NEN)
Impact of ccfDNA on clinical decision making in NEN patients
Saussez Sven & Verset Laurine
Université de Mons & Institut Jules Bordet
239 677 €
Cancer de la zone tête et cou
Radiothérapie
Development of a targeted theranostic platform combining magnetic nanoparticles and radiotherapy for head and neck cancer treatment
Sotiriou Christos
ULB
600 000 €
Cancer du sein
Decoding metastatic breast cancer heterogeneity using spatial transcriptomics and AI in the AURORA study
Tejpar Sabine
KU Leuven
449 500 €
Cancer colorectal
Using mucins as friends in colorectal cancer diagnostics and treatment
Van den Eynde Marc
UCLouvain
249 500 €
Cancer colorectal
Dimensional characterization of immune and T cells population in metastatic colorectal cancer for the development of circulating immune biomarker.
Van de Veken Pieter
UAntwerpen
450 000 €
Cancer du colon
Diagnostic and theranostic targeting of fibroblast activation protein (FAP) with gold nanoparticles decorated with FAPIs and FAPI fragments.
Veldeman Liv & Remouchamps Vincent
UGent & CHU UCL Namur
599 000 €
Cancer du sein
Radiothérapie
Prolonged abdominal deep-inspiration breath hold: clinical translation, monitoring and assessment of cardiac and lung toxicity reduction in prone crawl radiotherapy of breast cancer

Amiante : 7 projets - € 1 943 370

Équipe(s) de recherche
Institution(s)
Montant
Thème de recherche
Titre du projet
Bisteau Xavier
ULB
245 000 €
Mésothéliome et traitement ciblé
Exploiting the sensitivity of malignant pleural mesothelioma to CDK4 inhibitory drugs
Cataldo Didier
ULiège
200 000 €
Mésothéliome et traitement ciblé
CCL5-CCR5 axis : a therapeutic target in cisplatin resistant mesothelioma?
Gevaert Kris & Lamote Kevin
UGent & UAntwerpen
249 350 €
Mésothéliome
Validation of a protein biomarker panel in exhaled breath condensate
Huaux François
UCLouvain
313 600 €
Mésothéliome
Syndecan-1-expressing macrophages: a new immunosuppressive entity in fibre-induced cancer
Meylan Etienne
ULB
375 420 €
Mésothéliome
Analyses of the tumor immune compartment and tumor-associated neutrophils in new generation mouse models of malignant mesothelioma
Willems Luc
ULiège
240 000 €
Mésothéliome
Eosinophils propel extracellular traps on mesothelioma cells and inhibit chemoimmunotherapy
Zhu Jingjing
Institut de Duve
320 000 €
Mésothéliome
Regulation of anti-tumor immunity by the aryl hydrocarbon receptor in asbestos-induced mesothelioma